Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

3.900 UNCHANGED
Streaming Delayed Price Updated: 1:10 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Kezar Narrows Loss 37 Percent in Q2
Via The Motley Fool
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study
Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable safety review. 
Via Benzinga
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use. 
Via Benzinga
Looking Into Kezar Life Sciences's Recent Short Interest
 
Via Benzinga
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in... 
Via Benzinga
Analyst Expectations for Kezar Life Sciences's Future
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
Kezar Life Sciences' zetomipzomib drug for lupus nephritis has been placed on clinical hold by the FDA following serious safety concerns. The company continues its autoimmune hepatitis trials while... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases. 
Via Benzinga
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries. 
Via InvestorPlace
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology. 
Via InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
When you want to light your afterburners, these ideas will do the trick. 
Via InvestorPlace
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await. 
Via InvestorPlace
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining. 
Via Benzinga
Topics Initial Public Offering
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth. 
Via InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
 
Via Benzinga
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Top 5 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.